Morepen Labs Completes Phase-1 Capacity Expansion

has successfully completed the first phase of its manufacturing capacity expansion programme ahead of schedule. The company’s installed reactor capacity for API and CDMO operations has increased from 535 KL to 614 KL. The early completion of this phase strengthens Morepen’s ability to support growing demand in its active pharmaceutical ingredients and contract development and manufacturing organisation businesses. The expansion forms part of a multi-phase roadmap aimed at scaling capacity to meet larger global CDMO opportunities and higher-value manufacturing requirements. By enhancing reactor capacity ahead of schedule, Morepen is better positioned to execute on existing mandates and pursue additional partnerships. The development underscores the company’s focus on operational readiness and timely infrastructure upgrades to support its growth strategy in the pharmaceutical manufacturing space. *Top stocks in the API & CDMO industry:* Laurus Labs, Divi’s Laboratories, and Solara Active Pharma Sciences.